8-K: Seer Receives Revised Acquisition Bids

Seer, Inc. confirms receipt of two revised, unsolicited acquisition proposals, one from the Radoff-JEC Group for $2.55 per share and another from CEO Omid Farokhzad for $2.45 per share plus contingent value rights.

Summary

• Seer, Inc. has received two revised, non-binding acquisition proposals.
• The Radoff-JEC Group proposed to acquire all outstanding shares for $2.55 per share in cash, plus a contingent value right.
• Omid Farokhzad, M.D., Seer's Chair and CEO, submitted a revised proposal to acquire all shares for $2.45 per share in cash, plus two separate contingent value rights (CVRs).
• Dr. Farokhzad's proposal includes a tiered Revenue-Linked CVR of up to $0.33 per share and a tiered Sale-Linked CVR of up to $4.91 per share, extending CVR expiration dates to 2033.
• The Special Committee of Seer's Board of Directors will review both proposals and other alternatives.
• No stockholder action is required at this time.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as it indicates continued interest and revised offers for the company, with potential for significant upside, though the ultimate outcome remains uncertain and contingent on negotiations and shareholder approval.

Positives

• Receipt of multiple unsolicited acquisition proposals indicates potential interest in the company's value.
• Dr. Farokhzad's revised proposal offers significant potential upside through CVRs, extending their term to 2033 to maximize value realization.
• Dr. Farokhzad's proposal is not subject to a financing contingency.
• Dr. Farokhzad's proposal aims to accelerate certainty and cash delivery to stockholders through a potential two-step merger structure.

Negatives

• Both proposals are non-binding and unsolicited.
• The cash component of Dr. Farokhzad's proposal remains at $2.45 per share, unchanged from his prior offer.
• The Radoff-JEC Group's proposal offers a higher upfront cash price ($2.55) but with a single contingent value right.
• The ultimate value of Dr. Farokhzad's proposal is contingent on future revenue and sale milestones, with uncertain realization.

Risks

• The proposals are non-binding and subject to negotiation, due diligence, majority-of-the-minority shareholder approval, and regulatory approvals.
• There is uncertainty regarding the final terms and the likelihood of either proposal being accepted and consummated.
• Potential conflicts of interest exist given that the CEO is one of the bidders.
• The company's future performance is subject to risks and uncertainties as detailed in its SEC filings.

Future Outlook

The company's Special Committee will review the acquisition proposals and other strategic alternatives. Dr. Farokhzad's proposal includes extended CVR terms to 2033, aiming to achieve higher revenue milestones and a more favorable sale or disposition of the company or its assets.

Management Comments

• The Special Committee of Seer's Board of Directors, in consultation with its advisors, will carefully review and consider both proposals, as well as other alternatives available to Seer, and determine the course of action that it believes is in the best interests of Seer and all Seer stockholders.
• Omid Farokhzad, M.D. stated that his revised proposal provides stockholders with certain, near-term cash through an upfront payment while also preserving meaningful upside participation through two CVR instruments.
• Dr. Farokhzad noted that preserving the Company's cash balance at closing is essential to appropriately capitalizing Seer for the next phase of execution and to funding continued investment in the Proteograph platform, commercial expansion, and pipeline development.
• Dr. Farokhzad expressed his commitment to a rigorous, independent, and fair process and is prepared to engage constructively with the Special Committee.
• Dr. Farokhzad encouraged the Special Committee to consider parallel-tracking its engagement with him alongside any other assessment of strategic alternatives.

Industry Context

StockSavvy.ai notes that the receipt of multiple unsolicited acquisition proposals, especially one from the CEO, is a significant event in the biotechnology sector, often indicating a perceived undervaluation by external parties or internal strategic shifts. The inclusion of contingent value rights tied to revenue and future sale events is a common mechanism in such deals to bridge valuation gaps and incentivize future performance.

Comparison to Industry Standards

• The proposed cash consideration of $2.55 per share from Radoff-JEC Group represents a 41% premium over Seer's 30-day VWAP as of June 30, 2026, which is within the typical range for acquisition premiums in the biotech sector, though specific benchmarks vary widely based on company stage and technology.
• Omid Farokhzad's revised proposal, with a maximum potential value of $7.69 per share (including CVRs), offers a significantly higher potential upside compared to the Radoff-JEC Group's offer. The structure with extended CVRs to 2033 is designed to capture the long-term value of the Proteograph platform, a strategy sometimes seen in deep tech or platform-based biotech companies aiming for substantial future market penetration.
• The structure of the Sale-Linked CVR, with payouts up to $4.91 per share tied to a transaction value exceeding $2.0 billion, suggests an expectation of a substantial future exit valuation for Seer, which would be a strong outcome if achieved, but is highly speculative at this stage.

Management Changes

Corporate Governance

Related Party Transactions

• Omid Farokhzad, M.D., the company's Chair and CEO, has submitted a revised, unsolicited, non-binding acquisition proposal to acquire all outstanding shares of the company in his personal capacity as a stockholder.

Stakeholder Impact

• Shareholders: Will be presented with two revised acquisition offers, one with a higher upfront cash component and another with a lower upfront cash component but significant potential upside through contingent value rights.
• Employees: The future of the company's operations, headquarters, and investment in the Proteograph platform may be impacted depending on which proposal, if any, is accepted.
• Management: The CEO is a bidder, creating potential conflicts and requiring recusal from board decisions.

Next Steps

• The Special Committee will review both acquisition proposals and other strategic alternatives.
• The Special Committee will determine the course of action in the best interests of Seer and its stockholders.
• Dr. Farokhzad requests engagement on his Revised Proposal and public disclosure of its terms.
• Dr. Farokhzad suggests parallel-tracking engagement with him alongside other strategic alternative assessments.
• Dr. Farokhzad proposes a two-step merger for a quick closing by the end of September 2026.

Key Dates

Recommendation

The company is in active discussions regarding potential acquisition offers, with a CEO-involved bid presenting both opportunities and complexities. While the offers indicate potential value realization, the terms are still under negotiation, and the ultimate outcome is uncertain. A 'hold' recommendation is appropriate pending further clarity on the definitive terms and the Special Committee's evaluation.

Keywords

acquisition proposal, take-private, contingent value rights, proteomics, biotechnology, special committee, board of directors, corporate governance